

Fig. 1-A




Fig. 1-B




Fig. 1-C

Size: 0.6360 mg
 Method: 10 DEG C/MIN AMB TO 300
 Comment: SEALED PAN




Fig. 2-A

Size: 1.7840 mg
 Method: 10 DEG C/MIN AMB TO 300
 Comment: SEALED PAN




Fig. 2-B

Size: 1.4230 mg
 Method: 10 DEG C/MIN AMB TO 300
 Comment: SEALED PAN




Fig. 2-C

Size: 1.0400 mg
 Method: 10 DEG C/MIN AMB TO 300
 Comment: SEALED PAN




Fig. 2-D

Sample Weight: 15.300 mg
 Comment: N-Propyl Alcohol solvents
 unused pen




Fig. 2-E




Fig. 3-A

TO-20" S042F60




Fig. 3-B




Fig. 3-C

TOPOCHEM




Fig. 3-D

TD 220" 60427660




Fig. 4

FOZ240" E0447T660




Fig. 5




Fig. 6-A

FD4220" E044T660




Fig. 7




Fig. 8

TO 20" CH 260




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15





Fig. 16



Interaction of A: Cooling Rate and B: Purity

Fig. 17




Fig. 18




Fig. 19




Fig. 20

FOCUS" EDH.F660




Fig. 21




Fig. 22

Fig. 23
Study Schematic





Fig. 24
Baseline Demographics

BB	
Mean Age (Yrs.)	Pbo (N = 66)
	58.7
	55.4
Gender [N (%)]	Epl (N = 69)
Female	37 (56.1)
Male	34 (49.3)
	29 (43.9)
	35 (50.7)
Ethnicity [N (%)]	
Asian	0 (0.0)
Black	1 (1.4)
Caucasian	0 (0.0)
Other	1 (1.5)
	65 (98.5)
	67 (97.1)
	0 (0.0)

Fig. 25
Baseline Weight, BP, Heart Rate


BB	
Mean Values	Pbo (N = 66)
	Epl (N = 69)
Weight (kg)	
Female	70.4
Male	88.9
BP (mmHg)	
SBP / DBP	157.2 / 98.8
	158.2 / 99.0
Heart Rate (bpm)	
	65.7
	68.7

Fig. 26
Mean Change From Baseline in BP
Week 8 (Final Visit)



*Adjusted to treatment, center, and baseline value

Fig. 27
Mean Change in BP (Each Visit):
BB and Eplerenone



*Adjusted to treatment, center, and baseline value

Fig. 28
Active Renin and Aldosterone:
BB and Eplerenone




Fig. 29
Adverse Events

Adverse Events	BB	
	Pbo (N = 66)	Epl (N = 69)
Hyperkalemia	0	4*
Hyperuricemia	0	0
Increased Lab Values		
GGT	0	0
SGOT	0	0
SGPT	0	0
BUN	0	0
Impotence	0	0
Gynecomastia	0	0
Hypotension	0	0
Menstrual Irregularities	0	0

* 3 cases of hyperkalemia resolved spontaneously with continued treatment, and one patient was withdrawn